Working at Abcuro
At Abcuro, we’re dedicated to developing breakthrough therapeutics for high unmet needs in autoimmune disease and cancer. To achieve this important goal, we have assembled an experienced and dedicated team that shares a passion for bringing meaningful therapeutic advances to patients.
Our team is deeply curious, analytical, and driven to make a difference for patients. If you share these qualities and believe our mission, we’d love to hear from you.
OPEN POSITIONS
Director, QA Compliance
Abcuro, Inc. is a clinical-stage biotechnology company developing protein-based treatments for serious autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ulviprubart (ABC008), a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle
Senior Director, Regulatory CMC
Abcuro, Inc. is a clinical-stage biotechnology company developing protein-based treatments for serious autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ulviprubart (ABC008), a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle
Senior Manager, CMC Cell Culture Manufacturing
Abcuro, Inc. is a clinical-stage biotechnology company developing protein-based treatments for serious autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ulviprubart (ABC008), a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle
